Translational Development Acquisition Corp. (NASDAQ:TDACU – Get Free Report) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 96 shares, a growth of ∞ from the May 14th total of 0 shares. Based on an average daily volume of 2,588 shares, the days-to-cover ratio is currently 0.0 days.
Translational Development Acquisition Trading Up 1.0%
Shares of NASDAQ TDACU traded up $0.12 during mid-day trading on Friday, reaching $11.62. 3,439 shares of the company were exchanged, compared to its average volume of 4,227. Translational Development Acquisition has a 1 year low of $10.71 and a 1 year high of $17.29. The firm has a 50-day moving average of $11.19 and a 200 day moving average of $10.72.
Translational Development Acquisition Company Profile
Translational Development Acquisition Corp. is a blank check acquisition company incorporated in Delaware. The company was formed to effect a merger, stock purchase, asset acquisition, stock exchange, reorganization or similar business combination with one or more businesses, though it has not yet identified a target for its initial transaction.
In early 2021, the company completed its initial public offering and listed its units on the Nasdaq under the ticker TDACU. Each unit comprises one Class A ordinary share and one-third of a warrant to purchase additional Class A shares, with its securities also trading separately as shares and warrants.
Following its IPO, the net proceeds from the offering are held in a trust account until the closing of an initial business combination.
Further Reading
- Five stocks we like better than Translational Development Acquisition
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
